NovaTears+Omega-3 for evaporative dry eye approved in Europe

NovaTears+Omega-3 has been approved in Europe for the treatment of signs and symptoms of evaporative dry eye disease, according to a Novaliq press release.

The first eye drop to have high concentrations of omega-3 (0.2%) ethyl ester of plant origin, NovaTears+Omega-3 stabilizes the lipid layer of the tear film and reduces evaporation of the underlying water phase of the tear film, supplementing the lipid layer with omega-3 fatty acids, the release said.

“The addition of omega-3 fatty acids to an already powerful NovaTears eye drop will provide dry eye patients with additional relief and physiological benefits by stabilizing the lipid layer,” Jerry Cagle, PhD, a member of Novaliq’s supervisory board, said in the release.

NovaTears+Omega-3 has been approved in Europe for the treatment of signs and symptoms of evaporative dry eye disease, according to a Novaliq press release.

The first eye drop to have high concentrations of omega-3 (0.2%) ethyl ester of plant origin, NovaTears+Omega-3 stabilizes the lipid layer of the tear film and reduces evaporation of the underlying water phase of the tear film, supplementing the lipid layer with omega-3 fatty acids, the release said.

“The addition of omega-3 fatty acids to an already powerful NovaTears eye drop will provide dry eye patients with additional relief and physiological benefits by stabilizing the lipid layer,” Jerry Cagle, PhD, a member of Novaliq’s supervisory board, said in the release.